Biopharmaceutical company developing and commercializing products for the treatment of heart failure and infectious diseases.
scPharmaceuticals Inc., a dedicated pharmaceutical firm, specializes in advancing and bringing to market a range of innovative pharmaceutical products. At the forefront of its offerings is FUROSCIX, the company's flagship product candidate. FUROSCIX utilizes a formulation of furosemide delivered via an on-body infusor, specifically designed to manage congestion in patients suffering from heart failure.
In addition to FUROSCIX, scPharmaceuticals Inc. is actively developing scCeftriaxone, an antibiotic aimed at treating infections caused by both gram-positive and gram-negative organisms. The company's pipeline also includes the scCarbapenem program, an antibiotic intended for the treatment of infections caused specifically by gram-negative organisms.
scPharmaceuticals Inc. collaborates closely with industry partners to enhance its product offerings. Notably, the company has a development agreement with West Pharmaceutical Services, Inc. to advance the development of the single-use SmartDose device, aimed at optimizing drug delivery technologies.
Founded in 2013 and headquartered in Burlington, Massachusetts, scPharmaceuticals Inc. continues to expand its capabilities and product portfolio, leveraging innovative solutions to address critical medical needs. With a commitment to advancing patient care through cutting-edge pharmaceuticals, the company remains poised to make significant strides in the healthcare industry.